Neil L. Berinstein
Affiliations: | University of Toronto, Toronto, ON, Canada |
Area:
Immunology, Molecular BiologyGoogle:
"Neil Berinstein"Children
Sign in to add traineeLaurent K. Verkoczy | grad student | 2000 | University of Toronto |
Ali A. Zarrin | grad student | 2000 | University of Toronto |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Pucilowska J, Egan J, Berinstein N, et al. (2019) Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC) Cancer Research. 79 |
Berinstein N, Bence-Buckler I, Laneuville P, et al. (2019) SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Hematological Oncology. 37: 569-569 |
Wolf GT, Moyer JS, Kaplan MJ, et al. (2018) IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Oncotargets and Therapy. 11: 3731-3746 |
Abdul-Wahid A, Cydzik M, Fischer NW, et al. (2018) Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. International Journal of Cancer |
Berinstein NL, McNamara M, Nguyen A, et al. (2018) Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology. 7: e1423173 |
Berinstein NL, Pennell NM, Weerasinghe R, et al. (2018) Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with Y ibritumomab tiuxetan in a phase II study. Hematological Oncology |
Smyth L, Buckstein R, Pennell N, et al. (2018) Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology |
Page DB, Pucilowska J, Berinstein NL, et al. (2018) Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy. Journal of Clinical Oncology. 36: 7-7 |
Smyth L, Buckstein R, Nancy P, et al. (2017) Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α Blood. 130: 4069-4069 |
Berinstein N, Smyth L, Pennell N, et al. (2017) PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α Hematological Oncology. 35: 365-366 |